Kā sazināties ar centru
HCP centrs
Par pacientiem rūpējas īpaša multidisciplināra komanda, kas viņus uzņem un vada ārstniecības procesā, tostarp oftalmologi, ortoptisti un medmāsas, kas specializējas diagnostikas un rehabilitācijas tehnikās, konsultanti un orientācijas un mobilitātes operatori, lai pabeigtu kvalifikācijas/rehabilitācijas kursu, kā arī pediatri, audiologi, neirologi, nefrologi sindromisko formu diagnostikai un ārstēšanai.
Lai pieteiktu pirmo diagnostisko dienas stacionāru, zvaniet Reto acu slimību centram pa tālruņa numuru: 081 566 67 62 (katru otrdienu un ceturtdienu no plkst. 11.00 līdz 13.00).
Lai pieteiktu turpmākās vizītes ambulatori (pēcpārbaude), sazinieties ar uzņēmumu CUP pa tālruņa numuru: 800 177 780, norādot savas patoloģijas nosaukumu.
Attēls: Falk2, izmantojot Wikimedia Commons
Sazināties
AOU Università degli Studi della Campania Luigi Vanvitelli, Napoli, Italy
Komanda
Pr Francesca Simonelli
Itālija
Pr Francesco Testa
Itālija
Dr Valentina Di Iorio
Itālija
Dr Raffaella Brunetti Pierri
Itālija
Klīniskie izmēģinājumi
An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects G (p.Cys998X) Mutation.
Phase 3 Randomized, Controlled Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Phase 3 Follow-up Study of AAV5-hRKp.RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene
Clinical and Molecular Studies in Families With Inherited Eye Disease
Natural history of patients with inherited retinal diseases due to mutations in RPE65 gene
Safety and Efficacy of Emixustat in Stargardt Disease.
Natural History Study in Subjects With Usher Syndrome.
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 1/2 Multicenter, Open-label, Dose Escalation, Safety and Efficacy Study of Subretinal Administration of Dual AAV8.MYO7A, AAVB-081 in Subjects With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
A Multicenter, Prospective, Longitudinal, Observational Study in Children and Adults With Stargardt Disease Related Atrophy Secondary to Biallelic Mutations in the ABCA4 Gene